$45.99 / month – $389.99
Vilon peptide (KE) is a Khavinson dipeptide bioregulator targeting thymic and immune tissue. This research-grade compound modulates gene expression in thymocytes and T-lymphocytes for preclinical immunosenescence, inflammation, and lifespan research. 20mg lyophilized powder, =98% purity, COA included.
Vilon peptide is a synthetic dipeptide bioregulator with the amino acid sequence Lys-Glu (KE), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Vilon targets thymic tissue and the broader immune system, functioning as a thymus bioregulator that modulates gene expression in thymocytes, T-lymphocytes, and supporting immune cells. It belongs to the Khavinson bioregulator peptides class — short regulatory peptides that exhibit tissue-specific gene expression modulation at physiological concentrations — and has been studied extensively in preclinical models of immune aging, inflammation, cancer immunosurveillance, and thymic involution.
Vilon holds a distinctive position among the Khavinson bioregulators as one of the most extensively sudied peptides in the entire bioregulatory system. Its minimal dipeptide structure (just two amino acids) represents the smallest functional unit capable of tissue-specific gene expression modulation, making it a foundational research tool for understanding the minimal structural requirements of peptide bioregulation. Research spanning over three decades has examined vilon’s effects on immune function, tumor immunosurveillance, chronic inflammation, and lifespan extension in multiple model organisms. PrymaLab Vilon 20mg is manufactured to high purity standards and supplied exclusively for qualified preclinical research.
| Specification | Detail |
|---|---|
| Compound | Vilon (dipeptide bioregulator) |
| Sequence | Lys-Glu (KE) |
| Quantity | 20mg |
| Target Tissue | Thymus, T-lymphocytes, immune system |
| Class | Khavinson bioregulator peptide (short regulatory peptide) |
| Purity | ≥98% (HPLC-verified per batch) |
| Testing | HPLC, mass spectrometry, identity verification |
| Form | Lyophilized powder |
| Storage | Store at −20°C desiccated; protect from light |
| Intended Use | Preclinical research only — not for human or veterinary therapeutic use |
Vilon operates through the peptide-DNA interaction mechanism described by Professor Khavinson’s research group, where the Lys-Glu dipeptide selectively binds specific DNA sequences within gene promoter regions and modulates chromatin conformation. In thymic and immune tissue, vilon influences the expression of genes governing T-cell development, immune cell differentiation, cytokine production, and immunosurveillance. Despite its minimal two-amino-acid structure, vilon demonstrates reproducible tissue-specific transcriptional effects at physiologically relevant concentrations.
The thymus undergoes progressive involution beginning in early adulthood, resulting in declining T-cell output, reduced immune diversity, and impaired adaptive immunity. This age-related thymic decline is a central driver of immunosenescence. Vilon peptide research has demonstrated modulation of thymic epithelial cell gene expression, enhanced thymocyte maturation, and improved T-cell receptor repertoire diversity in aged experimental models. These findings position vilon as a key research tool for studying thymic rejuvenation strategies.
As a dipeptide, vilon represents the minimal functional unit in the Khavinson bioregulator system. Research into how just two amino acids can produce tissue-specific gene expression changes has been fundamental to understanding the broader mechanisms of peptide bioregulation. The Lys-Glu sequence has been shown to interact with specific DNA motifs enriched in immune-related gene promoters, providing evidence for sequence-specific rather than charge-based peptide-DNA interactions.
Published studies report multiple immune-related and anti-aging effects of vilon peptide across diverse experimental models. All findings described below are from preclinical animal and cell culture research.
Age-related immune decline (immunosenescence) involves reduced T-cell output, skewed cytokine profiles, and impaired pathogen response. Vilon research has consistently demonstrated restoration of T-lymphocyte subpopulations, normalized CD4/CD8 ratios, enhanced natural killer cell activity, and improved cytokine balance in aged animal models. These immune restoration effects represent some of the most robust and replicated findings in the entire bioregulator peptide literature.
Chronic low-grade inflammation (“inflammaging”) is a hallmark of biological aging that drives tissue damage across multiple organ systems. Vilon peptide research reports downregulation of pro-inflammatory gene expression (including IL-6, TNF-α, and NF-κB pathway components) and upregulation of anti-inflammatory and regulatory mediators. This anti-inflammatory profile positions vilon as a research compound for studying the intersection of immune aging and systemic inflammation.
Among the most significant areas of vilon research is its reported enhancement of immune-mediated tumor surveillance. Preclinical studies have demonstrated improved natural killer cell cytotoxicity, enhanced T-cell-mediated tumor recognition, and reduced tumor growth rates in multiple experimental cancer models. These findings suggest that vilon’s immune-restorative effects extend to the anti-tumor arm of adaptive immunity, making it relevant to cancer immunology research.
Longitudinal studies by the Khavinson group have reported that vilon administration is associated with increased mean and maximum lifespan in multiple animal models. These lifespan observations, combined with the parallel improvement in immune parameters, support the hypothesis that immune system restoration is a key mechanism of anti-aging bioregulator effects and that thymic function plays a central role in biological aging trajectories.
Beyond adaptive immunity, vilon research has shown effects on hematopoietic stem cell function, including improved colony-forming capacity and normalized white blood cell counts in aged and immunosuppressed models. These hematopoietic effects extend vilon’s research relevance beyond pure immunology into stem cell biology and regenerative medicine applications.
Published research provides context for vilon peptide dosage parameters across experimental paradigms. The following represents reported dosage ranges from preclinical literature and is intended solely to inform research protocol design.
| Research Application | Reported Dosage Range | Protocol Context |
|---|---|---|
| Cell Culture (Thymocytes/T-cells) | 1–100 nM | Gene expression and differentiation studies |
| Immune Aging Models | 0.5–10 µg/kg | Chronic administration in aged rodent immune restoration studies |
| Tumor Immunosurveillance Models | 1–10 µg/kg | Immune enhancement in experimental tumor paradigms |
| Lifespan Studies | 0.5–5 µg/kg | Chronic low-dose regimens in longitudinal aging models |
Important: These are reported research dosages from published preclinical literature. Optimal dosing depends on experimental design, animal model, route of administration, and research objectives. This product is not intended for therapeutic use.
Researchers studying immune aging often compare vilon and thymogen because both function as thymus-targeting bioregulator peptides within the Khavinson system. Understanding their structural and functional differences is essential for selecting the appropriate immune bioregulator peptide for specific research applications.
| Feature | Vilon | Thymogen |
|---|---|---|
| Classification | Thymus bioregulator (immune system) | Thymus bioregulator (immune system) |
| Sequence | Lys-Glu (KE) | Glu-Trp (EW) |
| Peptide Length | Dipeptide (2 amino acids) | Dipeptide (2 amino acids) |
| Primary Mechanism | Broad immune gene expression modulation; T-cell development | Thymic peptide hormone pathway; T-cell maturation signaling |
| Key Research Focus | Immunosenescence, inflammation, cancer immunosurveillance, lifespan | Thymic function, T-cell maturation, immune reconstitution |
| Inflammatory Profile | Strong anti-inflammatory gene modulation (IL-6, TNF-α, NF-κB) | Immune balancing with less emphasis on inflammaging |
| Cancer Research | Extensive tumor immunosurveillance data | Less studied in direct tumor models |
| Lifespan Data | Multiple lifespan extension studies published | Fewer direct lifespan studies; focus on immune parameters |
| Combined Use | Complementary: broad immune + thymic-specific pathways | Complementary: thymic-specific + broad immune pathways |
While both vilon and thymogen target the thymus and immune system, they approach immune bioregulation through partially overlapping but distinct gene expression programs. Vilon has a broader research base spanning inflammation, cancer, and lifespan, while thymogen provides more targeted thymic function modulation. Combined protocols using both peptides may offer comprehensive immune system bioregulation for aging research.
PrymaLab supplies Vilon 20mg as a high-purity research-grade thymus bioregulator peptide verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Analysis. Independent third-party testing ensures unbiased quality verification and full traceability for GLP-compliant immunology and aging research.
Vilon is a synthetic dipeptide bioregulator (Lys-Glu, KE) developed by Professor Khavinson targeting the thymus and immune system. It modulates gene expression in thymocytes, T-lymphocytes, and supporting immune cells. Research applications include immunosenescence, inflammation, cancer immunosurveillance, and lifespan extension in preclinical models.
Published preclinical research reports vilon peptide benefits including restored T-lymphocyte subpopulations and normalized immune parameters in aged models, anti-inflammatory gene modulation (reduced IL-6, TNF-α, NF-κB), enhanced natural killer cell activity and tumor immunosurveillance, improved hematopoietic stem cell function, and increased mean and maximum lifespan in multiple animal models. All benefits are from preclinical research.
Both vilon (KE) and thymogen (EW) are thymus-targeting dipeptide bioregulators, but they modulate partially distinct gene expression programs. Vilon has a broader research base spanning inflammation, cancer immunosurveillance, and lifespan studies, while thymogen provides more focused thymic function and T-cell maturation modulation. Combined protocols may offer comprehensive immune bioregulation.
Published vilon dosage ranges include 1–100 nM for cell culture studies and 0.5–10 µg/kg for in vivo aging models. Dosing depends on experimental design, model system, and research objectives. This product is for preclinical research only and is not intended for therapeutic dosing.
Store lyophilized vilon at −20°C, desiccated and protected from light, for 24+ months stability. After reconstitution, store at 2–8°C and use within 2–4 weeks. Aliquot to avoid freeze-thaw cycles.
For Research Use Only. PrymaLab Vilon 20mg is intended exclusively for qualified preclinical research use. This product is not intended for human consumption, therapeutic use, veterinary treatment, or any application outside controlled research environments. Vilon has not been approved by the FDA or any equivalent regulatory authority for therapeutic use. All research applications described are from published preclinical and gerontological literature. Researchers are responsible for regulatory compliance.
| Weight | N/A |
|---|---|
| Dimensions | N/A |
Only logged in customers who have purchased this product may leave a review.
support@prymalab.net info@prymalab.net
30 Day return window. Satisfaction guaranteed or your money back.
All orders over %150 in value will receive free shipping.
Reviews
There are no reviews yet.